Updates are available Correction dated 2023-04-26
Click to view Correction: https://doi.org/10.1186/s13046-023-02668-3
-
Authors
Cole, Christopher B.
Morelli, Maria Pia
Fantini, Massimo https://orcid.org/0000-0002-8164-2587
Miettinen, Markku
Fetsch, Patricia
Peer, Cody
Figg, William D.
Yin, Tyler
Houston, Nicole
McCoy, Ann
Lipkowitz, Stanley
Zimmer, Alexandra
Lee, Jung-min
Pavelova, Miroslava
Villanueva, Erin N.
Trewhitt, Kathryn
Solarz, B. Brooke
Fergusson, Maria
Mavroukakis, Sharon A.
Zaki, Anjum
Tsang, Kwong Y.
Arlen, Philip M.
Annunziata, Christina M.
-
Funding
Funding for this research was provided by:
Precision Biologics, Inc
National Cancer Institute
- License Information
-
More Information
Article History
Received: 9 January 2023
Accepted: 20 March 2023
First Online: 29 March 2023
Change Date: 26 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13046-023-02668-3
Declarations
:
: The study was approved by NCI, NIH, Institutional Review Board (protocol code NCT03476681, first approved 03/26/2018; latest update 01/08/2020) and all participants signed a written informed consent.
: All data generated or analyzed during this study are included in this published article [and its supplementary information files].Data not shown in the manuscript are available from the corresponding author on reasonable request.
: All patients gave written informed consent.All authors have read and approved of its submission to this journal.
: MF, SAM, AZ, KYT and PMA are employees of Precision Biologics, Inc. PMA has an ownership interest in Precision Biologics, Inc. PMA had no role in the design of the study, in the collection, analyses or interpretation of the data, in the writing of the manuscript or in the decision to publish the results. All other authors have no conflicts of interest to declare.
